Pfizer partners with Voyager on AAV capsids

By The Science Advisory Board staff writers

October 7, 2021 -- Pfizer has signed a deal to exercise its options to license novel capsids generated from Voyager Therapeutics' RNA-driven Tracer (tropism redirection of adeno-associated virus by cell-type-specific expression of RNA) screening technology.

Pfizer may use the platform to develop, manufacture, and commercialize gene therapies, utilizing two undisclosed transgenes to treat certain neurological and cardiovascular diseases. Proprietary adeno-associated virus (AAV) capsids derived from Voyager's platform have shown superior blood-brain-barrier penetration, enhanced cardiac muscle tropism, and increased transgene expression in target tissues compared to conventional AAV capsids in non-human primates, according to Voyager.

Voyager will receive $30 million and is entitled to receive up to $20 million in fees for two options that Pfizer can exercise within the next year. In addition, Voyager is eligible to earn up to $580 million in total development, regulatory, and commercial milestones associated with licensed products.

Pfizer plans to acquire Trillium Therapeutics for $2.26B
Pfizer plans to acquire immuno-oncology drug developer Trillium Therapeutics for $2.26 billion in a deal that will expand Pfizer's portfolio to include...
Voyager advances gene therapy platform for CNS diseases
Voyager Therapeutics has launched new gene therapy programs for Huntington's disease, amyotrophic lateral sclerosis caused by mutation in the SOD1 gene,...
Neurocrine, Voyager tout gene therapy clinical results for Parkinson's disease
Neurocrine Biosciences and Voyager Therapeutics have released data from a phase Ib open-label, three-year efficacy and safety study of NBIb-1817, an investigational...

Copyright © 2021

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter